Novel symmetrical nucleotide-(5',5')-dimers of 3'-0acetylthymidine, 3'-0-methylthymidine, 3'-0-ethylthymidine, 3'-0-n-propylthymidine and 3'-azido-3'-deoxythymidine (AZT) were synthesized as membrane soluble pro-drugs. These were prepared using phosphorodichloridate chemistry and were characterised by spectroscopic and analytical data. In-vitro evaluation of the derivatives in cells acutely infected with the human immunodeficiency virus (HIV-1) demonstrated a range of activities. These derivatives were generally found to display poor inhibition of HIV proliferation. Derivatives containing AZT moieties were found to be potent, but such compounds were less active than the parent nucleoside. The data indicated that the AZT-containing compounds act primarily via the release of the free nucleoside. However, in some cases, the dimers of certain inactive nucleoside analogues were found to be active. In these cases, release of the nucleoside alone cannot account for the activity.
Introduction
The HIV life cycle of replication has been intensively studied over the past decade (Fisher et al., 1986; Luciw et al., 1987; Terwilliger et al., 1989) and each stage of the replication cycle can be a potential target for the design of antiviral drugs. One unique stage is the reverse transcriptase-catalysed synthesis of viral DNA from viral RNA (Baltimore, 1970; Temin and Mizutani, 1970) . This process has been the major target of antiviral agents, and the largest group of drugs is represented by the nucleoside analogues.
Prodrugs have been designed as the masked (neutral) mononucleoside phosphotriesters (Farrow et al., 1990; Jones et al., 1991; McGuigan et al., 1992; Perigaud et al., 1994; Wagner et al., 1995) or as the dinucleoside phosphotriesters (Busso et al., 1988; Schinazi et al., 1990; Puech et al., 1992; Shimizu et al., 1992) with the view of intracellular release of the parent nucleoside monophosphate. Thus, by employing membrane-soluble prodrugs, the first step of nucleoside activation would be bypassedthe so called 'kinase bypass strategy ' (McGuigan et al., 1993) .
In this communication, the synthesis and biological evaluation of a number of symmetrical nucleotide-(5',5')dimer phosphotriester derivatives of 3'-modified nucleosides, including AZT is reported. These derivatives were designed with a view to yielding intracellularly both nucleoside and nucleoside-5'-monophosphate components upon hydrolysis.
Results
3'-O-Acetylthymidine (1a) was synthesised by standard procedures (Michelson and Todd, 1953) and AZT (1e) was prepared using Mitsunobu conditions (Mitsunobu et al., 1971; Czernecki and Valery, 1991) . , ethyl (1c) and n-propyl (1d)] were synthesised using a modification of published strategies (Hampton et al., 1982; Herdewijn et al., 1987) . Thus, 5'-O-tritylthymidine (Weimann and Khorana, 1962) was allowed to react with the appropriate alkyl iodide and sodium hydride, in THF, followed by acid-mediated detritylation using acetic acid. Purification by column chromatography gave the products 1b-t d in yields of 63-75%. The structure and purity of the products 1b-1d were confirmed by NMR CH and 13C) and analytical data.
The synthetic route employed for the synthesis of the dimer phosphate derivatives was a direct coupling between the relevant nucleoside and the appropriate phosphorodichloridate in pyridine. Thus, phenyl phosphorodichloridate was reacted with each of the nucleosides 1a-1 e to yield the dimers 2a-2e in 30-50% yields. Similarly, the reaction of the nucleosides 1a-1c with 2,2dichloroethyl phosphorodichloridate (Magolda and Johnson, 1985) gave the nucleotides 3a-3c in similar yields. Nucleosides 1a-1 c were treated with 2,2,2trichloroethyl phosphorodichloridate to afford the products 4a-4c. Also, treatment of the nucleosides ta, 1c and 1e with 2,2,2-trifluoroethyl phosphorodichloridate yielded the products5a-5c.
The dimers 2a-2e, 3a-3c, 4a-4c and 5a-5c were isolated either as gums or as foamy solids. The structure and purity of these dimers were established by spectroscopic and analytical data. Phosphorus-31 NMR spectral data revealed a single resonance for each of the dimers at a chemical shift consistent with their structures. Evidence supporting the dimeric structures was evident from H-1, carbon-13 NMR and mass spectroscopic data. Carbon-13 (Tables 1 and 2) and H-1 NMR spectral data were informative but were very complex due to coupling effects. Moreover, both proton and carbon-13 NMR spectral data revealed the non-equivalence of the two nucleoside moieties. For example, the proton NMR spectrum of compound 2a displayed two distinct singlets of similar intensity for the base NH and 5-Me protons, and its carbon-13 NMR spectrum revealed two distinct doublets (each with phosphorus coupling constants of 7 Hz) for the C-4' carbon atom.
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Carbon-13 NMR spectral data also revealed 2-and 3bond phosphorus coupling in the phosphate region. For example, the 2,2,2-trifluoroethyl phosphate dimer derivatives 5a-5c displayed their carbon atoms as doublets of quartets. POCH 2 was noted at 64 with phosphorus couplings of 4-5 Hz and fluorine couplings of 37-38 Hz. The CF s group was noted more downfield, at 122-123, with fluorine coupling constants of 270-278 Hz and phosphorus coupling constants of 37-38 Hz. Mass spectra were also consistent with the proposed structures 2a-2e, 3a-3c, 4a-4c and 5a-5c and the purity of the derivatives was confirmed by analytical HPLC.
Discussion
The anti-HIV activities and cytotoxicities of the compounds 2a-2e, 3a-3c, 4a-4c and 5a-5c and their parent nucleosides 1a-1ewere measured in C8166lymphoblastoid cells acutely infected with HIV-1, and the results are presented in Table 3 . In-vitro studies generally revealed the compounds to display poor anti-HIV-1 activity. However, the compounds 2b, 2e, 4b, 4c and 5c reported here do show some anti-HIV-1 activity.
The 3'-O-acetyl phosphate dimers (2a, 3a, 4a and 5a) were all found to be inactive (ED so > 100 flM) in this assay. However, the 3'-O-methyl compound (2b) did display some activity. Substituting methyl (2b) by ethyl (2c) or n-propyl (2d) led to a marked decrease in activity. Compound 2b was found to have an ED so value of 20 flM whereas compounds 2c and 2d were devoid of anti-HIV 1 activity at concentrations up to 100 /lM. Extending the alkyl chain length at C-3' of the 2,2-dichloroethyl phosphate dimers (3b and 3c) also led to a decrease in activity. The decrease in activity was observed on substituting 3'-0-methyl (3b) to 3'-0-ethyl (3c): ED so = 10 /lM and 100 /lM, respectively. However, substituting 3'-0-methyl (4b) for 3'-0-ethyl (4c) in the 2,2,2-trichloroethyl phosphate dimer series led no change in activity.
3'-0-Methylthymidine (1b) was found to be inactive (Herdewijn et al., 1987) . Dimerization of 1b to the phenyl phosphate derivative 2b or the 2,2,-dichloroethyl phosphate derivative 3b led to a significant increase in activity (ED so = 10 /lM and 20 /lM, respectively), but the compound was poorly active (ED so = 90 /lM) when dimerised to the 2,2,2-trichloroethyl phosphate derivative (4b).
Although the lead compounds here (2b and 3b) were only weakly active, the data did reveal a significant difference with respect to the parent nucleoside 1b, and also a significant selectivity index in each case (2b >25 and 3b >100). However, dimerisation of 3'-0-ethylthymidine (1c) to the 2,2-dichloroethyl phosphate derivative (3c) or 2,2,2-trifluoroethyl phosphate derivative (5b) did not enhance the activity of the parent nucleoside; albeit the 2,2,2trichloroethyl phosphate derivative (4c) was found to be weakly active (ED so =50 /lM).
The AZT dimer phosphate derivatives 2e and 5c were found to exhibit marked anti-HIV-1 activity. Substituting phenyl (2e) for 2,2,2-trifluoroethyl (5c) gave insignificant changes in activity (0.8 /lM and 0.4 /lM, respectively) or cytotoxicity (500 /lM and 600 /lM, respectively). The AZT-derived compounds (2e and 5c) were found to be significantly less effective in JM cells (ED so values~1 00 /lM). It has been previously noted that AZT (1e) is very much less active in these cells (McGuigan et al., 1992) and the poor activity of the derivatives (2e and 5c) in this cell line indicates that these compounds may act primarily as depot forms of the free nucleoside (AZT). However, this mechanism alone would not account for the apparent activity of the phosphate dimers of the other 3'-substituted nucleosides (2b, 3b and 4c) where the free nucleosides are without activity, unless the dimers simply enhanced the intracellular delivery of the free nucleosides, which appears unlikely. Although the activity noted here is reasonably limited the indications of successful kinase bypass may warrant further study.
In conclusion, phosphate dimer derivatives of 3'-0methylthymidine (1b) bearing phenyl, di-and trichloroethyl groups are more active than their parent nucleosides against HIV proliferation, whereas AZT dimer phosphate derivatives bearing phenyl or trifluroroethyl groups are less active than AZT. The exact mechanism of action of the reported phosphate dimer derivatives is E0 5 0 is the minimum concentration of drug in 11M which will reduce HIV antigen production by 50%. CC 5 0 is the minimum drug concentration in 11M required to reduce the number of uninfected cells by 50%. NO refers to not determined.
unclear but there is an indication that the AZT phosphate dimers act primarily via the release of the parent nucleoside intracellularly, whereas the dimers derived from other nucleosides may not act entirely by this route.
Materials and Experimental Procedures: Chemistry
Ethyl acetate (EtOAc) and light petroleum (boiling range 40-60 DC) were distilled prior to use. Pyridine was distilled from calcium hydride onto potassium hydroxide pellets. All NMR spectral data were obtained in COCI 3. Phosphorus-31 NMR spectra were recorded on a JEOL JNM-FX 900 Fourier Transform NMR Spectrometer operating at 36 MHz and are reported in units of 0 relative to 85% phosphoric acid as the external standard, positive shifts are downfield. 1H and 13C spectra were measured using either a JEOL JNM-FX 900 spectrometer or JEOL JNM-GX 270 spectrometer. Mass spectral data and accurate mass data were obtained on a VG 70-250 Mass Spectrometer, courtesy of Dr G J Langley (University of Southampton). Reverse Phase analytical High Performance Liquid Chromatography (HPLC) was carried out using an ACS 350104 HPLC system with an ACS 750/12 UV detector on a techsphere 00S5 (250*4-6 mm) column. Mobile phase A = water, B = acetonitrile, gradient conditions 82% A 0 mln., 82% A 10 min., 20% A 30 min., 20% A 45 min., flow rate at 1 mL per minute.
3'-O-Acetylthymidilyl-(5',5')-3'-O-acetyl-5'-thymidilic acid, phenyl ester 2a
Under an atmosphere of nitrogen, phenyl phosphorodichloridate (0.29 g, 1.37 mmol) was added to a stirring solution of 3'-0-acetylthymidine (0.60 g, 2.11 mmol) in pyridine (20 mL). The reaction mixture was stirred at room temperature for 18 h. The solvent was removed and co-evaporated with toluene (4 x 20 mL) under reduced pressure. The product was purified by column chromatography on silica using ethyl acetate as eluent. Pooling and evaporation of appropriate fractions under reduced pressure gave a gum (0.29 g, 39%). 
3'-O-Methylthymidilyl-(5',5')-3'-O-methyl-5'-thymidilic acid, phenyl ester2b
This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 3 days and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.2 g of 3'-0methylthymidine was isolated 0.09 g (37% This was prepared by a method entirely analogous to that used tor compound 2a above, except that stirring was continued for 3 days and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.12 g of 3'-0ethylthymidine was isolated 0.07 g (47% Hz, J = 6.95 Hz); FAB MS (Argon, glycerol) m/e 701 (MNa+, 0.31%), 680 (MW, 13C, 0.08%), 679 (MW, 3%), 678 (M+, 0.11%), 93 (C 6HsO+, 50%), 81 (CsHsO+, base peak); MS accurate mass found 679.2365 (MH+, C30H40N4012P requires 679.2380); Analytical HPLC retention time: 32.10 min.
3 phenyl ester2d This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 3 days and the chromatographic purification utilised was ethyl acetate in petroleum ether (4:1). Thus, from 0.60 gof 3'-0-npropylthymidine was isolated 0.24 g (32%). op -5.45; 0H 9.81, 9.78 (2H, 2 x bs, 2 x NH), 7.24 (7H, m, 2 x H-6, Ph-H), 6.22, 6.17 (2H, 2 
3'-Azido-3'-deoxythymidilyl-(S',S')-3'-azido-3'-deoxy-S'thymidilic acid, phenyl ester2e
This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was at O°C for 1.5 h and then at room temperature for 18 h. Further phosphorylating agent (0.02 g, 0.08 mmol) was added, stirring continued for 2.5, and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.20 g of 3'azido-3'-deoxythymidine was isolated 0.04 g (16%); op -4.31; 0H 9. 81,9.76 3 2, This was prepared by a method entirely analogous to that used for compound 2a above, except that 0.5 equivalent of phosphorylating agent was used, stirring was continued for 3 days and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.12 g of 3'-0acetylthymidine was isolated 0.09 g (56% Nucleotide dimers as anti-HIV agents 335 2, This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 1 day and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.12 g of 3'-0methylthymidine was isolated 0.05 g (33% This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 1.5 days and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.12 g of 3'-0ethylthymidine was isolated 0.09 g (59% 
3'-O-Acetylthymidilyl-(S',S')-3'-O-acetyl-S'-thymidilic acid, 2,2,2-trichloroethyl ester 4a
This was prepared by a method entirely analogous to that used for compound 2a above, except that 0.5 equivalent of phosphorylating agent was used, stirring was continued for 2 days and the chromatographic purification utilised was methanol in chloroform (1:49). Thus, from 0.3 g of 3'-0acetylthymidine was isolated 0.08 g (20%). s, This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 19 h and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.16 g of 3'-0methylthymidine was isolated 0.10 g (46%). s, -3.84; 8 H 9.24 (2H, bs, 2 x NH), 7.34, 7.32 (2H, 2 x s, 2 x H-6), 6.19 (2H, m, 2 xH-1', J = 6.18 Hz), 4.61 (2H, m, POCH 2CCI3, J = 6.96 Hz), 4.37 (4H, m, 4 x H-5'), 4.17 (2H, m, 2 x H-3'), 4.02 (2H, m, 2 x H-4'), 3.36, 3.34 (6H, 2 x s, 2 x OCH 3), 2.43 (2H, m, 2 x H-2'), 2.16 (2H, rn, 2 x H-2'), 1.94 (6H, s, 2 x 5-CH 3); FAB MS (Argon, NBA) m/e 708 (M+, 2 x 37CI, 2%), 707 (MW, 37CI, 4%), 706 (M+, 37CI, 2%), 705 (MW, 5%), 81 (CsHsO+, 92%); Analytical HPLC retention time: 36.87 min.
3 2, 2, This was prepared by a method entirely analogous to that used for compound 2a above, except that stirring was continued for 2 days and the chromatographic purification utilised was methanol in chloroform (7:93). Thus, from 0.12 g of 3'-0ethylthymidine was isolated 0.07 g (44%). s, 0.27; 8 H 9.29
